Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 3/2017

11.03.2017 | Original Article

Outcome of Patients with Cervical and Vaginal Stump Carcinomas Treated with More Conservative Surgical Approaches: a 9-Year Experience of a Tertiary Oncology Center

verfasst von: Mohamed Hegazy, Ashraf Khater, Mohamed Awad, Sherif Kotb, Waleed Elnahas, Sameh Roshdy, Osama Eldamshety, Fayez Shahatto, Omar Farouk, Emadeldeen Hamed, Refaat Hegazi, Ola T. Abdel Dayem, Anas M. Gamal

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The surgical management of stump carcinoma includes the gold standard pelvic exenteration and more conservative approaches. This study aimed to investigate the outcome among a cohort of vaginal and cervical stump carcinomas that were treated with an intent of organ preservation. This is a prospective study of 60 patients with a biopsy confirmed stump carcinomas at a tertiary care oncology center in Egypt. The demographic, surgical, and pathological data were collected and patients underwent radical surgery with an intent of organ preservation guided by margin negativity. The pathologic data were correlated with the postoperative mortality. Correlation coefficients were calculated for simple correlation and regression analysis was used to investigate the independent predictors of survival. Pelvic exenteration was conducted in 30/60 (50%), while wide local excision with safety margins was possible in 26/60 (43%) and in two cases, resection was precluded. Mean hospital stay in days was 19 ± 9 (range 4–61). Overall operative morbidity was 83.3% (50/60). Perioperative mortality was 6.7% (4/60). Five-year disease-free survival was 40% (24/60). Five-year overall survival was 50% (30/60). The resection margin status and the perioperative therapy were independent prognostic factors of DFS (p = 0.003 and 0.02, respectively. Only the resection margin status was significantly associated with overall survival (p = 0.009). There was no increased mortality with introduction of more conservative surgical approaches. The resection margin status is the most important determinant of recurrence free and overall survivals.
Literatur
1.
Zurück zum Zitat Boyd SC, Look KY (2001) Prognostic factors for carcinoma of the cervical stump and cervical carcinoma associated with pregnancy. CME Journal of Gynecologic Oncology 6:347–356 Boyd SC, Look KY (2001) Prognostic factors for carcinoma of the cervical stump and cervical carcinoma associated with pregnancy. CME Journal of Gynecologic Oncology 6:347–356
2.
Zurück zum Zitat Gibbons SK, Keys HM (1996) Special situations in the management of early cervical cancer. In: Rubin SC, Hoskins WJ (eds) Cervical cancer and preinvasive neoplasia. Lippincott-Raven, Philadelphia, pp 259–260 Gibbons SK, Keys HM (1996) Special situations in the management of early cervical cancer. In: Rubin SC, Hoskins WJ (eds) Cervical cancer and preinvasive neoplasia. Lippincott-Raven, Philadelphia, pp 259–260
3.
Zurück zum Zitat Brunschwig A (1948) Complete excision of pelvic viscera for advanced carcinoma. Cancer 1:177–183CrossRefPubMed Brunschwig A (1948) Complete excision of pelvic viscera for advanced carcinoma. Cancer 1:177–183CrossRefPubMed
4.
Zurück zum Zitat Berek JS, Howe C, Lagasse LD, Hacker NF (2005) Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153–159CrossRefPubMed Berek JS, Howe C, Lagasse LD, Hacker NF (2005) Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153–159CrossRefPubMed
5.
Zurück zum Zitat Bramhall SR, Harrison JD, Burton A, Wallace DMA, Chan KK, Harrison G et al (1999) Phase II trial of radical surgery for locally advanced pelvic neoplasia. Br J Surg 86(6):805–812CrossRefPubMed Bramhall SR, Harrison JD, Burton A, Wallace DMA, Chan KK, Harrison G et al (1999) Phase II trial of radical surgery for locally advanced pelvic neoplasia. Br J Surg 86(6):805–812CrossRefPubMed
6.
Zurück zum Zitat Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15):3113–3119CrossRefPubMed Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15):3113–3119CrossRefPubMed
7.
Zurück zum Zitat McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol 101(2):296–304CrossRefPubMed McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol 101(2):296–304CrossRefPubMed
8.
Zurück zum Zitat Hatch KD, Berek JS (2005) Pelvic exenteration. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. 4th ed. Philadelphia’ Lippincott Williams and Wilkins, p 801–16 Hatch KD, Berek JS (2005) Pelvic exenteration. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. 4th ed. Philadelphia’ Lippincott Williams and Wilkins, p 801–16
9.
Zurück zum Zitat Ungar L, Palfalvi L, Novak Z (2008) Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol 111:S9–S12CrossRefPubMed Ungar L, Palfalvi L, Novak Z (2008) Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol 111:S9–S12CrossRefPubMed
10.
Zurück zum Zitat Fleisch MC, Pantke P, Beckmann MW, Schnuerch HG, Ackermann R, Grimm MO, Bender HG, Dall P (2007) Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 95(6):476–484CrossRefPubMed Fleisch MC, Pantke P, Beckmann MW, Schnuerch HG, Ackermann R, Grimm MO, Bender HG, Dall P (2007) Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 95(6):476–484CrossRefPubMed
11.
Zurück zum Zitat Maggioni A, Roviglione G, Landoni F, Zanagnolo V, Peiretti M, Colombo N, Bocciolone L, Biffi R, Minig L, Morrow CP (2009) Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol Oncol 114(1):64–68CrossRefPubMed Maggioni A, Roviglione G, Landoni F, Zanagnolo V, Peiretti M, Colombo N, Bocciolone L, Biffi R, Minig L, Morrow CP (2009) Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol Oncol 114(1):64–68CrossRefPubMed
12.
Zurück zum Zitat Kaur M, Joniau S, D'Hoore A, Van Calster B, Van Limbergen E, Leunen K, Penninckx F, Van Poppel H, Amant F, Vergote I (2012) Pelvic exenterations for gynecological malignancies: a study of 36 cases. Int J Gynecol Cancer 22(5):889–896CrossRefPubMed Kaur M, Joniau S, D'Hoore A, Van Calster B, Van Limbergen E, Leunen K, Penninckx F, Van Poppel H, Amant F, Vergote I (2012) Pelvic exenterations for gynecological malignancies: a study of 36 cases. Int J Gynecol Cancer 22(5):889–896CrossRefPubMed
13.
Zurück zum Zitat Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH (2009) Total pelvic exenteration for primary and recurrent malignancies. World J Surg 33(7):1502–1508CrossRefPubMedPubMedCentral Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH (2009) Total pelvic exenteration for primary and recurrent malignancies. World J Surg 33(7):1502–1508CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A (2006) Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 103:1023–1030CrossRefPubMed Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A (2006) Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 103:1023–1030CrossRefPubMed
15.
Zurück zum Zitat Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP (2005) Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer. Int J Gynecol Cancer 15:624–629CrossRefPubMed Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP (2005) Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer. Int J Gynecol Cancer 15:624–629CrossRefPubMed
16.
Zurück zum Zitat Sharma S, Odunsi K, Driscoll D, Lele S (2005) Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute. Int J Gynecol Cancer 15:475–482CrossRefPubMed Sharma S, Odunsi K, Driscoll D, Lele S (2005) Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute. Int J Gynecol Cancer 15:475–482CrossRefPubMed
17.
Zurück zum Zitat Yoo HJ, Lim MC, Seo SS, Kang S, Yoo CW, Kim JY, Park SY (2012) Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol 23(4):242–250CrossRefPubMedPubMedCentral Yoo HJ, Lim MC, Seo SS, Kang S, Yoo CW, Kim JY, Park SY (2012) Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol 23(4):242–250CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Jäger L, Nilsson PJ, Rådestad AF (2013) Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. Int J Gynecol Cancer 23(Issue 4):755–762CrossRefPubMed Jäger L, Nilsson PJ, Rådestad AF (2013) Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. Int J Gynecol Cancer 23(Issue 4):755–762CrossRefPubMed
Metadaten
Titel
Outcome of Patients with Cervical and Vaginal Stump Carcinomas Treated with More Conservative Surgical Approaches: a 9-Year Experience of a Tertiary Oncology Center
verfasst von
Mohamed Hegazy
Ashraf Khater
Mohamed Awad
Sherif Kotb
Waleed Elnahas
Sameh Roshdy
Osama Eldamshety
Fayez Shahatto
Omar Farouk
Emadeldeen Hamed
Refaat Hegazi
Ola T. Abdel Dayem
Anas M. Gamal
Publikationsdatum
11.03.2017
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 3/2017
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-017-0640-7

Weitere Artikel der Ausgabe 3/2017

Indian Journal of Surgical Oncology 3/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.